Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 NKG2D Ligands in Cancer Immunotherapy: Target or Not?

Literature DB >> 25485307

NKG2D Ligands in Cancer Immunotherapy: Target or Not?

Jennifer Wu¹.

Abstract

Entities: Chemical Disease Gene Species

Year: 2014 PMID： 25485307 PMCID： PMC4257473

Source DB: PubMed Journal: Austin J Clin Immunol

× No keyword cloud information.

26 in total

1. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA.

Authors: Stefan Holdenrieder; Petra Stieber; Andrea Peterfi; Dorothea Nagel; Alexander Steinle; Helmut Rainer Salih
Journal: Cancer Immunol Immunother Date: 2006-04-25 Impact factor: 6.968

2. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.

Authors: Hyunkeun Song; JeongKi Kim; David Cosman; Inpyo Choi
Journal: Cell Immunol Date: 2006-04-21 Impact factor: 4.868

3. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases.

Authors: Gang Liu; Catherine L Atteridge; Xuanjun Wang; Ashley D Lundgren; Jennifer D Wu
Journal: J Immunol Date: 2010-03-05 Impact factor: 5.422

4. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.

Authors: Claire L Sutherland; N Jan Chalupny; Kenneth Schooley; Tim VandenBos; Marek Kubin; David Cosman
Journal: J Immunol Date: 2002-01-15 Impact factor: 5.422

5. ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients.

Authors: Roger W McGilvray; Robert A Eagle; Phil Rolland; Insiya Jafferji; John Trowsdale; Lindy G Durrant
Journal: Int J Cancer Date: 2010-09-01 Impact factor: 7.396

6. A second lineage of mammalian major histocompatibility complex class I genes.

Authors: S Bahram; M Bresnahan; D E Geraghty; T Spies
Journal: Proc Natl Acad Sci U S A Date: 1994-07-05 Impact factor: 11.205

7. ULBP6/RAET1L is an additional human NKG2D ligand.

Authors: Robert A Eagle; James A Traherne; James R Hair; Insiya Jafferji; John Trowsdale
Journal: Eur J Immunol Date: 2009-11 Impact factor: 5.532

Review 8. Advantages and clinical applications of natural killer cells in cancer immunotherapy.

Authors: Erik Ames; William J Murphy
Journal: Cancer Immunol Immunother Date: 2013-08-30 Impact factor: 6.968

9. Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D.

Authors: Louise Bacon; Robert A Eagle; Martina Meyer; Nicholas Easom; Neil T Young; John Trowsdale
Journal: J Immunol Date: 2004-07-15 Impact factor: 5.422

10. Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma.

Authors: C S Vetter; W Lieb; E-B Bröcker; J C Becker
Journal: Br J Cancer Date: 2004-10-18 Impact factor: 7.640

4 in total

1. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.

Authors: Shengjun Lu; Jinyu Zhang; Dai Liu; Guangfu Li; Kevin F Staveley-O'Carroll; Zihai Li; Jennifer D Wu
Journal: Clin Cancer Res Date: 2015-06-23 Impact factor: 12.531